Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma

NCT00187486 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT00187486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00187486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2004
Completion date
March 31, 2011
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, gliosarcoma